Pliant Therapeutics, Inc.

Pliant Therapeutics is a drug development company working on cancer treatments based on a technology called integrin inhibitors. The company's main drug candidate, PLN-101095, is an oral medication that blocks two types of proteins called integrins, which may help fight solid tumors. The company is still in early-stage testing with this drug. Pliant has built a library of over 15,000 molecules designed to target integrins, which it uses to discover new drug candidates.